Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

161. Global Strategy for Diagnosis, Management, and Prevention of COPD

Global Strategy for Diagnosis, Management, and Prevention of COPD Global Strategy for Diagnosis, Management, and Prevention of COPD - 2016 - Global Initiative for Chronic Obstructive Lung Disease - GOLD Global Strategy for Diagnosis, Management, and Prevention of COPD – 2016 [/vc_column_text][/vc_column][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ width=”1/6″][/vc_column][/vc_row][vc_row type (...) ″][vc_column_text] Please reference this document as follows: From the Global Strategy for the Diagnosis, Management and Prevention of COPD , Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. Available from: https://goldcopd.org/. GOLD documents are protected by copyright. A single copy of this document may be downloaded for your own educational use, but copies may not be made for distribution or posted on a website without authorization from GOLD. Click here to by the GOLD Science Committee

2016 European Respiratory Society

162. Co-morbidities in 99 COPD patients: A case series from Syria (PubMed)

Co-morbidities in 99 COPD patients: A case series from Syria To assess the most frequent co-morbidities in chronic obstructive pulmonary disease (COPD) patients.We studied 99 patients, including 72 males and 67 smokers, presented to our University Hospital in Lattakia, Syria in 2012, with a mean age of 63 years.Overall, there were 61% hypertension, 37% ischemic heart disease, 25% diabetes, 45% anemia, and 47% pulmonary hypertension. Other diseases were less significant. Patients who had more (...) severe Global Initiative for Chronic Obstructive Lung Disease stage had a greater number of co-morbidities.We recommend as a general practice, to assess cardiac co-morbidities, hypertension, and other co-morbidities in all COPD patients and vice versa. We also recommend performing spirometry in smokers complaining of chronic cough, sputum, or dyspnea for early diagnosis of COPD.

Full Text available with Trip Pro

2015 Journal of translational internal medicine

163. Distractive Auditory Stimuli in the Form of Music in Individuals With COPD: A Systematic Review (PubMed)

Distractive Auditory Stimuli in the Form of Music in Individuals With COPD: A Systematic Review Music has been used as a distractive auditory stimulus (DAS) in patients with COPD, but its effects are unclear. This systematic review aimed to establish the effect of DAS on exercise capacity, symptoms, and health-related quality of life (HRQOL) under three conditions: (1) during exercise training, (2) during exercise testing, and (3) for symptom management at rest.Randomized controlled (...) or crossover trials as well as cohort studies of DAS during exercise training, during formal exercise testing, and for symptom management among individuals with COPD were identified from a search of seven databases. Two reviewers independently assessed study quality. Weighted mean differences (WMDs) with 95% CIs were calculated using a random-effects model.Thirteen studies (12 of which were randomized controlled or crossover trials) in 415 participants were included. DAS increased exercise capacity when

2015 EvidenceUpdates

164. Glycopyrronium bromide. Seebri, Enurev Breezhaler in COPD. We´re not breathing anything new under the sun

Glycopyrronium bromide. Seebri, Enurev Breezhaler in COPD. We´re not breathing anything new under the sun 2015. DAR No 1: Glycopyrronium bromide. Seebri Breezhaler®, Enurev Breezhaler® in COPD - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 1: Glycopyrronium bromide. Seebri Breezhaler®, Enurev Breezhaler® in COPD DAR No 1: Glycopyrronium bromide. Seebri Breezhaler®, Enurev Breezhaler® in COPD Content tools Share it We´re not breathing (...) anything new under the sun Glycopyrronium bromide is an inhaled long-acting muscarinic antagonist (LAMA) approved for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD). The only head-to-head trial published to date showed noninferiority vs tiotropium but not superiority. The average change with respect to baseline FEV1 trough was 103 mL (glycopyrronium) vs 99 mL (tiotropium), but there was no clinical relevance (120 mL). Safety profile remains inconclusive given

2015 Drug and Therapeutics Bulletin of Navarre (Spain)

165. An Internet-Mediated Pedometer-Based Program Improves Health-Related Quality-of-Life Domains and Daily Step Counts in COPD: A Randomized Controlled Trial (PubMed)

An Internet-Mediated Pedometer-Based Program Improves Health-Related Quality-of-Life Domains and Daily Step Counts in COPD: A Randomized Controlled Trial Low levels of physical activity (PA) are associated with poor outcomes in people with COPD. Interventions to increase PA could improve outcomes.We tested the efficacy of a novel Internet-mediated, pedometer-based exercise intervention. Veterans with COPD (N = 239) were randomized in a 2:1 ratio to the (1) intervention group (Omron HJ-720 ITC

Full Text available with Trip Pro

2015 EvidenceUpdates

166. Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality

Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality BestBets: Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption (...) of chronic obstructive pulmonary disease (COPD)] can [use of a procalcitonin algorithm compared to physician gestalt] result in [lower rates of antibiotic consumption with no adverse effects] Clinical Scenario A 78 year old female presents to your emergency department reporting increased wheezing over the last 24 hours. She reports a mildly productive cough and denies fever. A chest x-ray reveals no clear evidence of pneumonia. In addition to therapy for what you believe is a COPD exacerbation, you

2015 BestBETS

167. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4) (PubMed)

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4) Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with the mono-components was evaluated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials. Patients received tiotropium+olodaterol FDC 2.5/5 μg or 5/5 μg, tiotropium 2.5 μg or 5 μg, or olodaterol 5 μg

Full Text available with Trip Pro

2015 EvidenceUpdates

168. Prophylactic antibiotics for individuals with Chronic Obstructive Pulmonary Disease (COPD): a rapid review

Prophylactic antibiotics for individuals with Chronic Obstructive Pulmonary Disease (COPD): a rapid review Prophylactic antibiotics for individuals with Chronic Obstructive Pulmonary Disease (COPD): a rapid review Prophylactic antibiotics for individuals with Chronic Obstructive Pulmonary Disease (COPD): a rapid review Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Health Quality Ontario. Prophylactic antibiotics for individuals with Chronic Obstructive Pulmonary Disease (COPD): a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions The evidence yielded mixed results on the effectiveness and safety of the prophylactic use of the antibiotic azithromycin (AZM) for COPD patients. From the examination of 1 systematic review of RCTs (in Rapid Review, proper): Compared

2015 Health Technology Assessment (HTA) Database.

169. Respiratory therapy services in home care for individuals with chronic obstructive pulmonary disease (COPD): a rapid review

Respiratory therapy services in home care for individuals with chronic obstructive pulmonary disease (COPD): a rapid review Respiratory therapy services in home care for individuals with chronic obstructive pulmonary disease (COPD): a rapid review Respiratory therapy services in home care for individuals with chronic obstructive pulmonary disease (COPD): a rapid review Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Respiratory therapy services in home care for individuals with chronic obstructive pulmonary disease (COPD): a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions There were no studies that reported the effect of RT services on the time interval between acute exacerbations. Based on the results of a very small RCT with serious

2015 Health Technology Assessment (HTA) Database.

170. Pulmonary rehabilitation setting for adults with chronic obstructive pulmonary disease (COPD): an economic rapid review

Pulmonary rehabilitation setting for adults with chronic obstructive pulmonary disease (COPD): an economic rapid review Pulmonary rehabilitation setting for adults with chronic obstructive pulmonary disease (COPD): an economic rapid review Pulmonary rehabilitation setting for adults with chronic obstructive pulmonary disease (COPD): an economic rapid review Bermingham SL Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Bermingham SL. Pulmonary rehabilitation setting for adults with chronic obstructive pulmonary disease (COPD): an economic rapid review. Toronto: Health Quality Ontario (HQO). Economic Rapid Review. 2015 Authors' conclusions This literature review could not determine whether hospitals or home and community locations are the most cost-effective setting for pulmonary rehabilitation programs for adults with COPD. We

2015 Health Technology Assessment (HTA) Database.

171. Cognitive-behavioural therapy for anxiety and depression in patients with chronic obstructive pulmonary disease (COPD): a rapid review

Cognitive-behavioural therapy for anxiety and depression in patients with chronic obstructive pulmonary disease (COPD): a rapid review Cognitive-behavioural therapy for anxiety and depression in patients with chronic obstructive pulmonary disease (COPD): a rapid review Cognitive-behavioural therapy for anxiety and depression in patients with chronic obstructive pulmonary disease (COPD): a rapid review Health Quality Ontario Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Cognitive-behavioural therapy for anxiety and depression in patients with chronic obstructive pulmonary disease (COPD): a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions Cognitive-behavioural therapy did not significantly reduce symptoms of anxiety or depression in patients with mild to severe

2015 Health Technology Assessment (HTA) Database.

172. Exercise programs after pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD): a rapid review

Exercise programs after pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD): a rapid review Exercise programs after pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD): a rapid review Exercise programs after pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD): a rapid review Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Exercise programs after pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD): a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions There was no evidence found on exercise programs for pneumonia patients. Despite some methodological flaws, based on 1 meta-analysis of 6 randomized

2015 Health Technology Assessment (HTA) Database.

173. Airway clearance techniques for patients with stable chronic obstructive pulmonary disease (COPD): a rapid review

Airway clearance techniques for patients with stable chronic obstructive pulmonary disease (COPD): a rapid review Airway clearance techniques for patients with stable chronic obstructive pulmonary disease (COPD): a rapid review Airway clearance techniques for patients with stable chronic obstructive pulmonary disease (COPD): a rapid review Wang M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Wang M. Airway clearance techniques for patients with stable chronic obstructive pulmonary disease (COPD): a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions One systematic review was included that examined airway clearance techniques for patients with stable COPD. The 19 studies (4 of which were only available as abstracts) were generally of low quality, based on risk of bias assessment; due

2015 Health Technology Assessment (HTA) Database.

174. Pulmonary rehabilitation in the home versus other settings for individuals with chronic obstructive pulmonary disease (COPD): a rapid review

Pulmonary rehabilitation in the home versus other settings for individuals with chronic obstructive pulmonary disease (COPD): a rapid review Pulmonary rehabilitation in the home versus other settings for individuals with chronic obstructive pulmonary disease (COPD): a rapid review Pulmonary rehabilitation in the home versus other settings for individuals with chronic obstructive pulmonary disease (COPD): a rapid review Wang M Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wang M. Pulmonary rehabilitation in the home versus other settings for individuals with chronic obstructive pulmonary disease (COPD): a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions One relevant systematic review by Vieira et al 2010 was identified and within the review four relevant RCTs compared home-based pulmonary

2015 Health Technology Assessment (HTA) Database.

175. Self-care support for people with COPD

Self-care support for people with COPD This evidence briefing has been produced by the Centre for Reviews and Dissemination. Full details of methods are available on request (paul.wilson@ york.ac.uk or liz.bickerdike@york.ac.uk). The content of this briefing was judged to be up to date as of June 2014. The briefing has been produced as part of independent research funded by the NIHR Health Services and Delivery Research programme (Project ref: 12/5002/18). The views expressed (...) in this publication are those of the authors and do not necessarily reflect those of the NIHR or the Department of Health. • As the prevalence of long-term conditions increases there is a greater focus on encouraging people to manage their condition(s). • Self-care has been identified as integral to maintaining the health and wellbeing of people with COPD. • There is consistent evidence that multicomponent interventions reduce respiratory-related hospital admissions and improve quality of life for people

2015 Evidence briefings

176. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score (PubMed)

Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score Patients with chronic obstructive pulmonary disease (COPD) are at high risk for lung cancer (LC) and represent a potential target to improve the diagnostic yield of screening programs.To develop a predictive score for LC risk for patients with COPD.The Pamplona International Early Lung Cancer Detection Program (P-IELCAP) and the Pittsburgh Lung Screening Study (...) (PLuSS) databases were analyzed. Only patients with COPD on spirometry were included. By logistic regression we determined which factors were independently associated with LC in PLuSS and developed a COPD LC screening score (COPD-LUCSS) to be validated in P-IELCAP.By regression analysis, age greater than 60, body mass index less than 25 kg/m(2), pack-years history greater than 60, and emphysema presence were independently associated with LC diagnosis and integrated into the COPD-LUCSS, which ranges

Full Text available with Trip Pro

2015 EvidenceUpdates

177. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study (PubMed)

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose (...) bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD.This multicentre, blinded, triple-dummy, parallel-group, non-inferiority study randomised patients aged ≥40 years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥30% to <80% predicted) to QVA149 110/50 µg o.d. or TIO 18 µg o.d.+ FOR 12 µg twice daily (1:1) for 26 weeks. The primary endpoint was to demonstrate non-inferiority

Full Text available with Trip Pro

2015 EvidenceUpdates

178. Umeclidinium/vilanterol (as trifenatate) (Anoro Ellipta) - chronic obstructive pulmonary disease (COPD)

Umeclidinium/vilanterol (as trifenatate) (Anoro Ellipta) - chronic obstructive pulmonary disease (COPD) Final Appraisal Recommendation Advice No: 0215 – February 2015 Umeclidinium/vilanterol (as trifenatate) (Anoro ® Ellipta ® ? ) 55 micrograms/22 micrograms inhalation powder Submission by GlaxoSmithKline UK In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1038), which includes the AWMSG Secretariat (...) to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

2015 All Wales Medicines Strategy Group

179. In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia?

In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? BestBets: In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? Report By: Mark Woods - Consultant in Emergency Medicine Search checked by David Hodgson - ST5 Emergency Medicine Institution: Whiston (...) Hospital, Merseyside, UK and Mersey School of Emergency Medicine, UK Date Submitted: 31st August 2012 Date Completed: 10th March 2015 Last Modified: 11th March 2015 Status: Green (complete) Three Part Question In [patients with an Acute Exacerbation of COPD] can a [normal venous blood gas CO2] [rule out arterial hypercarbia]? Clinical Scenario A 74 year old male patient with known COPD presents acutely breathless with widespread wheeze. He refuses an arterial blood gas (ABG) and complains that last

2015 BestBETS

180. Mortality risk prediction in COPD by a prognostic biomarker panel (PubMed)

Mortality risk prediction in COPD by a prognostic biomarker panel Chronic obstructive pulmonary disease (COPD) is a complex disease with various phenotypes. The simultaneous determination of multiple biomarkers reflecting different pathobiological pathways could be useful in identifying individuals with an increased risk of death. We derived and validated a combination of three biomarkers (adrenomedullin, arginine vasopressin and atrial natriuretic peptide), assessed in plasma samples of 385 (...) patients, to estimate mortality risk in stable COPD. Biomarkers were analysed in combination and defined as high or low. In the derivation cohort (n = 142), there were 73 deaths during the 5-year follow-up. Crude hazard ratios for mortality were 3.0 (95% CI 1.8-5.1) for one high biomarker, 4.8 (95% CI 2.4-9.5) for two biomarkers and 9.6 (95% CI 3.3-28.3) for three high biomarkers compared with no elevated biomarkers. In the validation cohort (n = 243), 87 individuals died. Corresponding hazard ratios

Full Text available with Trip Pro

2015 EvidenceUpdates